Atrial fibrillation: will new drugs and patient choice improve anticoagulation outcomes?

Atrial fibrillation: will new drugs and patient choice improve anticoagulation outcomes?

The growing epidemic of atrial fibrillation presents major challenges to the healthcare community, both clinical and financial.

New options in anticoagulation for atrial fibrillation.

The presence of atrial fibrillation significantly increases the risk and burden of thromboembolic stroke.1 Warfarin is the reference standard treatment for the primary prevention of embolic stroke during atrial fibrillation.2 However, the long-term use of warfarin has its limitations. Although guidelines suggest a target international normalized ratio (INR) of 2.5 (range, 2.0 to 3.0) for this i...

Anticoagulation in Atrial Fibrillation

Atrial fibrillation (AF) is the most commonly occurring arrhythmia. An antithrombotic agent is considered mandatory as part of the management in most patients with AF. It has been conclusively demonstrated that long-term anticoagulation therapy can significantly reduce the risk of stroke in patients with non-valvular AF. While vitamin K antagonists (VKAs) such as warfarin are highly effective, ...

Anticoagulation in atrial fibrillation

Atrial fibrillation (AF) affects approximately 300,000 Australians and has a growing prevalence. It is associated with high rates of death and disability. The majority of people with AF are eligible to be treated with anticoagulant medications, but practice is often inadequate, leaving many people at risk of stroke. Until recently, the only antithrombotics available to prevent stroke in people ...

New device for stroke prevention in atrial fibrillation as an alternative to anticoagulation drugs.